메드팩토

235980KOSDAQ자연과학 및 공학 연구개발업

58.1 / 100

Reference Date: 2026-07-24

Financial Score22.5 / 40

News Sentiment20.6 / 25

Momentum5.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 11.1% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Medfact is a biotech company established in 2013, specializing in the development of innovative drugs for refractory cancers using advanced genomic analysis technology. Its flagship product, Vactosertib, targets the TGF-β1 signaling pathway to modulate the tumor microenvironment and enhance the efficacy of existing cancer treatments when used in combination. The company is currently conducting clinical trials for various cancers, including colorectal, pancreatic, and osteosarcoma.

Number of Employees

54people

Average Salary

57.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 43.644.0Point

PBR

2.03Industry Average 2.524.0Point

In line with industry avg

ROE

-24.70Industry Average -32.093.5Point

Below industry avg

Debt Ratio

2.86Industry Average 7.316.5Point

Half of industry avg (excellent)

Trend 2023~20254.5 / 10 points

Revenue Growth Rate

1.5 / 3

Operating Profit Growth Rate

3.0 / 3

Avg ▲29.9% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -41.5% (improving, 3yr)

Detailed News Sentiment

4 totalPositive 4Neutral 0Negative 0Average Sentiment Score 82.5

Positive
메드팩토, 차세대 파이프라인 임상 시동…'백토서팁 원툴' 벗어난다
메드팩토의 차세대 파이프라인 임상 진입으로 신약 개발 가속화 기대.
Positive
메드팩토, 뼈질환·자가면역질환 치료제 MP2021 호주 임상 1상 신청
메드팩토의 MP2021 치료제가 호주에서 임상 1상 시험 계획을 승인받아 긍정적인 시장 반응 예상.
Positive
메드팩토, 파골세포 억제제 ‘MP2021’ 호주 1상 신청
메드팩토의 파골세포 억제제 MP2021이 호주에서 임상 1상 시험 신청을 진행함으로써 신약 개발에 대한 긍정적인 진전을 보여주고 있다.

Detailed Momentum

52-week position1.0Point

Near 52w low (2%, downtrend)

Current 2,720Won52-week high 8,05052-week low 2,575

1-month return1.0Point

1m -11.11% (falling)

Volume trend3.0Point

Volume flat

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral주식매수선택권부여에관한신고2026-07-23
Neutral투자판단관련주요경영사항(임상시험계획승인신청) (MP2021 호주 임상1상 시험 계획 승인신청)2026-07-15